Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.89M | $1.92M | $1.99M | $4.23M | $17.4M | $43.5M | $51.5M | $58.4M | $63.7M | $52.0M |
| Revenue growth | — | 1.9% | 3.5% | 112.4% | 311.7% | 150.1% | 18.3% | 13.5% | 9.0% | -18.5% |
| Operating income | -$43.3M | -$61.9M | -$59.1M | -$85.8M | -$62.8M | -$78.0M | -$78.7M | -$82.4M | -$172M | -$270M |
| Operating margin | -2296.0% | -3220.1% | -2970.8% | -2029.9% | -361.1% | -179.3% | -152.7% | -141.0% | -269.6% | -519.8% |
| Net income | -$44.7M | -$63.4M | -$60.0M | -$86.4M | -$156M | -$6.55M | -$71.0M | -$80.7M | -$194M | -$266M |
| Net margin | -2369.0% | -3296.2% | -3014.0% | -2043.3% | -894.3% | -15.1% | -138.0% | -138.1% | -303.7% | -511.9% |
| EPS (diluted) | -$1.80 | -$2.20 | -$1.57 | -$1.91 | -$2.56 | -$0.98 | -$0.97 | -$1.02 | -$1.22 | -$1.42 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$34.0M | -$50.5M | -$49.2M | -$77.6M | -$53.6M | -$65.5M | -$59.6M | -$70.2M | -$135M | -$205M |
| Capital expenditures | $1.92M | $8.25M | $1.89M | $2.24M | $841K | $1.19M | $3.71M | $6.09M | $1.29M | $12.0M |
| Free cash flow | -$35.9M | -$58.7M | -$51.1M | -$79.8M | -$54.4M | -$66.7M | -$63.3M | -$76.3M | -$136M | -$217M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $32.9M | $41.5M | $54.1M | $54.4M | $228M | $164M | $102M | $196M | $392M | $737M |
| Total assets | $74.9M | $55.4M | $73.0M | $78.7M | $262M | $205M | $149M | $252M | $458M | $808M |
| Total liabilities | $22.9M | $29.3M | $37.2M | $82.4M | $186M | $117M | $114M | $161M | $143M | $154M |
| Shareholders' equity | $52.0M | $26.1M | $35.9M | -$3.63M | $76.1M | $88.0M | $35.4M | $91.1M | $315M | $654M |
| Retained earnings | -$174M | -$237M | -$297M | -$384M | -$539M | -$546M | -$617M | -$698M | -$891M | -$1.16B |
| Shares (wtd avg diluted) | 25.0M | 29.7M | 41.5M | 45.3M | 60.8M | 82.2M | 82.6M | 85.6M | 158M | 187M |
Every figure is extracted from OCULAR THERAPEUTIX, INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.